Home / Business and Economy / J&J Surges Past Patent Loss with New Drug Strength
J&J Surges Past Patent Loss with New Drug Strength
21 Jan
Summary
- New drug sales offset Stelara patent loss, boosting revenue.
- Company forecasts exceeding Wall Street expectations for 2026.
- Fourth-quarter net earnings rose 20.8% to $5.12 billion.
Johnson & Johnson has announced robust financial results for the latest quarter, with higher sales of drugs for cancer and autoimmune conditions significantly offsetting the impact of a key patent expiration. This strategic growth has led to increased revenue and profit for the company.
In the fourth quarter, net earnings rose by 20.8% to $5.12 billion. While the company experienced a nearly 48% plunge in sales for its former blockbuster drug Stelara due to competitor versions, newer treatments like Darzalex and Tremfya demonstrated substantial growth, with sales up nearly 27% and 68% respectively.
The company also provided an optimistic forecast for the upcoming year, projecting sales growth exceeding 6% and earnings per share of $11.53 on an adjusted basis. This outlook was issued despite anticipated impacts from tariffs and a recent agreement to reduce certain drug prices, indicating J&J's resilience and confidence in its pipeline.
Johnson & Johnson's pharmaceutical division reported a 10% sales increase for the quarter, and its medical-device business also contributed positively with 7.5% sales growth. The company's stock performance has been strong, with shares up approximately 48% over the past 12 months.
